Blood Transfusion Medicine Basics

Blood transfusion is a cornerstone of modern medicine, saving countless lives in trauma, surgery, and chronic disease management. However, it is a transplant of living tissue, carrying significant risks that must be meticulously managed. Understanding the immunology of blood groups, the procedures that ensure compatibility, and the spectrum of potential adverse reactions is fundamental for any clinician. This knowledge directly impacts patient safety, making the difference between a life-saving intervention and a catastrophic complication.

The Foundation: ABO and Rh Blood Group Systems

The ABO blood group system is the most critical determinant of transfusion compatibility. It is defined by the presence or absence of two antigens—sugar molecules—on the surface of red blood cells (RBCs): antigen A and antigen B. Your inherited genotype dictates your phenotype: Type A (A antigens), Type B (B antigens), Type AB (both A and B antigens), or Type O (neither antigen).

Crucially, individuals naturally produce antibodies against the A or B antigens they lack. These are called naturally occurring antibodies (IgM type) and are present without prior exposure to foreign RBCs. For example, a person with Type A blood has anti-B antibodies in their plasma. If they receive Type B blood, these pre-formed antibodies will immediately bind to the donor RBCs, causing rapid and severe destruction—an acute hemolytic transfusion reaction. This reciprocal relationship is why Type O blood, lacking A and B antigens, is considered the universal donor for RBCs, and Type AB is the universal recipient.

The Rh factor, specifically the D antigen, is the second most important blood group system. Unlike ABO antibodies, anti-D antibodies are not naturally occurring; they develop only after a person who is Rh-negative (lacks the D antigen) is exposed to Rh-positive blood through transfusion or pregnancy. This sensitization can lead to severe hemolytic reactions in future transfusions or cause hemolytic disease of the fetus and newborn in subsequent pregnancies. Therefore, Rh status is always determined alongside ABO type.

Pre-Transfusion Testing: Type and Screen & Crossmatch

Before any blood product is issued, two key laboratory procedures are performed to maximize safety. The type and screen is the first step. "Type" refers to determining the patient's ABO group and Rh status. "Screen" involves testing the patient's serum or plasma against a panel of reagent RBCs containing the most clinically significant non-ABO antigens (e.g., Kell, Duffy, Kidd). The goal is to detect any unexpected antibodies the patient may have developed from prior transfusions or pregnancies. If an antibody is detected, its specificity is identified, and antigen-negative donor blood must be located.

A crossmatch is the final compatibility test. The major crossmatch mixes the patient's serum with donor RBCs to confirm there are no antibodies in the patient that will react with the donor's cells. A positive crossmatch is an absolute contraindication to transfusion with that unit. In many hospitals, if the antibody screen is negative, an electronic crossmatch—a computer check verifying ABO/Rh compatibility—may be performed instead of a manual test for stable patients, speeding up the process. For patients with a history of antibodies or a positive screen, a full antiglobulin (Coombs) crossmatch is always required.

Acute Hemolytic and Febrile Non-Hemolytic Reactions

The most immediate and dangerous transfusion reaction is the acute hemolytic transfusion reaction (AHTR) most often due to ABO incompatibility. This is typically a result of clerical error, such as misidentifying the patient or the blood unit. Within minutes or hours, the recipient's pre-formed antibodies attack the donor RBCs, causing intravascular hemolysis. Symptoms include fever, chills, pain at the infusion site or in the flanks/back, hypotension, dark urine (hemoglobinuria), and disseminated intravascular coagulation (DIC). Treatment is immediate: STOP the transfusion, maintain intravenous access with normal saline, and provide aggressive supportive care to protect renal function and manage coagulopathy.

In contrast, a febrile non-hemolytic transfusion reaction (FNHTR) is common and much less severe. It is characterized by a temperature increase of $\ge 1°C$ during or shortly after transfusion, often with chills. The mechanism is typically due to cytokines in the donor blood product or the recipient's antibodies reacting against donor white blood cell (WBC) antigens. While not life-threatening, it is uncomfortable and must be distinguished from more serious reactions. Pre-storage leukoreduction (filtering WBCs from blood products) has significantly reduced the incidence of FNHTR.

TRALI, TACO, and the Massive Transfusion Protocol

Two life-threatening reactions that present with respiratory distress must be carefully differentiated. Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-related death. Its mechanism involves donor antibodies (usually against human leukocyte antigens, HLAs, or neutrophil antigens) that activate the recipient's neutrophils, causing capillary leak and non-cardiogenic pulmonary edema. It presents as acute hypoxemia and bilateral pulmonary infiltrates within 6 hours of transfusion. Treatment is supportive with oxygen and often mechanical ventilation. Risk mitigation includes using plasma primarily from male donors, who are less likely to have developed these antibodies.

Transfusion-associated circulatory overload (TACO) is pulmonary edema due to volume overload, typically in patients with compromised cardiac or renal function. Symptoms include tachycardia, hypertension, elevated jugular venous pressure, and dyspnea. Unlike TRALI, which causes low pressure edema, TACO features high pressure. Management involves stopping the transfusion, providing diuretics, and applying supplemental oxygen.

In scenarios of critical hemorrhage, a massive transfusion protocol (MTP) is activated. This is a coordinated, pre-planned delivery of large volumes of blood products—often in a balanced ratio approximating 1:1:1 of packed RBCs, plasma, and platelets. The goal is to replace lost blood volume, restore oxygen-carrying capacity, and correct coagulopathy simultaneously to prevent the "lethal triad" of acidosis, hypothermia, and coagulopathy. MTPs are guided by laboratory values (like fibrinogen and calcium levels) and often utilize rapid transfusion devices.

Common Pitfalls

1. Prioritizing Speed Over Safety: During an emergency, the urge to "hang blood" immediately is strong. However, skipping proper patient identification (checking two unique identifiers against the blood unit tag and patient wristband) is the most common root cause of fatal ABO-incompatible transfusions. Always follow the verification protocol, even in a code situation.
2. Attributing Respiratory Distress to "Allergy": New-onset respiratory symptoms during a transfusion are a medical emergency. Immediately assuming it is a mild allergic reaction (which typically presents with urticaria and itching) can delay the diagnosis of TRALI or TACO. Dyspnea, hypoxia, and crackles on exam require immediate cessation and a full clinical evaluation.
3. Misinterpreting a Febrile Reaction: While FNHTR is common, fever can also be the first sign of a hemolytic reaction or bacterial contamination of the blood product. A single episode may be managed as FNHTR, but any fever requires stopping the transfusion, assessing for other symptoms (like pain or hypotension), and re-checking patient and unit identification before considering it "just a febrile reaction."
4. Overlooking Hypocalcemia in Massive Transfusion: During rapid infusion of large volumes of blood products preserved with citrate, citrate can bind the recipient's ionized calcium, leading to symptomatic hypocalcemia (tingling, muscle cramps, prolonged QT interval, hypotension). This is a key supportive consideration during an MTP that is easily correctable with intravenous calcium chloride or gluconate.

Summary

• The ABO system is governed by naturally occurring antibodies; an incompatible transfusion causes immediate, catastrophic hemolysis. The Rh (D) antigen is critical for preventing sensitization, especially in individuals of childbearing potential.
• Pre-transfusion safety is ensured by the type and screen (to identify ABO/Rh and unexpected antibodies) and the crossmatch (the final compatibility check between patient serum and donor cells).
• Acute hemolytic transfusion reactions are medical emergencies typically due to ABO incompatibility and clerical error, requiring immediate cessation and aggressive supportive care.
• TRALI (non-cardiogenic edema from donor antibodies) and TACO (cardiogenic edema from volume overload) are critical differentials for transfusion-related respiratory distress.
• A massive transfusion protocol delivers balanced ratios of blood products to treat critical hemorrhage, aiming to correct oxygen-carrying capacity and coagulopathy while preventing the lethal triad of hypothermia, acidosis, and coagulopathy.